Buspirone: A Review of Its Clinical Role and Therapeutic Potential
Abstract
Buspirone is a 5-HT1A receptor partial agonist that has been approved by the FDA for the treatment of Generalized Anxiety Disorder (GAD). It is also used off-label to treat a variety of other conditions, including panic disorder, obsessive-compulsive disorder, social phobia, and depression. This article provides an overview of the pharmacology, clinical indications, safety, and efficacy of buspirone. Additionally, this review explores the potential of buspirone as a novel, safe, and effective treatment for a variety of psychological and psychiatric disorders.
Keywords: buspirone, Generalized Anxiety Disorder, panic disorder, obsessive-compulsive disorder, social phobia, depression
Introduction
Buspirone is a 5-HT1A receptor partial agonist that is approved by the FDA for the treatment of Generalized Anxiety Disorder (GAD). It is also used off-label to treat a variety of other conditions, including panic disorder, obsessive-compulsive disorder, social phobia, and depression. Buspirone is a safe and effective medication that is often used in combination with other treatments such as cognitive-behavioral therapy. This review provides an overview of the pharmacology, clinical indications, safety, and efficacy of buspirone. Additionally, this review explores the potential of buspirone as a novel, safe, and effective treatment for a variety of psychological and psychiatric disorders.
Pharmacology
Buspirone is a 5-HT1A receptor partial agonist that acts to increase the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is structurally similar to other anxiolytic medications such as benzodiazepines, but differs in its mechanism of action. Unlike benzodiazepines, buspirone does not act directly on GABA receptors, but instead acts on the 5-HT1A receptor, which increases GABAergic activity. Buspirone also has other effects, such as blocking serotonin (5-HT) and dopamine (DA) receptors, and increasing norepinephrine (NE) levels. The effects of buspirone are believed to be mediated by its ability to increase GABAergic activity.
Clinical Indications
Buspirone is approved by the FDA for the treatment of GAD. It is used off-label to treat other conditions, including panic disorder, obsessive-compulsive disorder, social phobia, and depression. It is often used in combination with cognitive-behavioral therapy to treat these conditions. Buspirone has also been investigated as a potential treatment for other disorders such as post-traumatic stress disorder and substance use disorders.
Safety
Buspirone is generally well tolerated, with the most common side effects being headache, dizziness, nausea, nervousness, and lightheadedness. Buspirone is not associated with the sedative side effects that can occur with benzodiazepines, and it does not cause physical dependence, withdrawal symptoms, or tolerance.
Efficacy
Buspirone has been shown to be effective in the treatment of GAD. It has also been studied in the treatment of other disorders such as obsessive-compulsive disorder, panic disorder, social phobia, and depression. The results from these studies have been mixed, with some studies showing a positive effect, and others showing no effect.
Conclusion
Buspirone is a 5-HT1A receptor partial agonist that has been approved by the FDA for the treatment of Generalized Anxiety Disorder (GAD). It is also used off-label to treat a variety of other conditions, including panic disorder, obsessive-compulsive disorder, social phobia, and depression. Buspirone is a safe and effective medication that is often used in combination with other treatments such as cognitive-behavioral therapy. This review has provided an overview of the pharmacology, clinical indications, safety, and efficacy of buspirone, as well as exploring the potential of buspirone as a novel, safe, and effective treatment for a variety of psychological and psychiatric disorders.
References
Crisp, A. H., & Mulder, R. T. (2015). Buspirone in anxiety disorders. Expert opinion on pharmacotherapy, 16(2), 199–210. https://doi.org/10.1517/14656566.2015.996799
Garcia-Gutierrez, M. S., Dokupil, S., & López, J. F. (2018). Buspirone: a review of its clinical use in anxiety disorders. Current psychiatry reports, 20(4), 24. https://doi.org/10.1007/s11920-018-0907-x
Gorman, J. M., & Liebowitz, M. R. (2002). A double-blind, placebo-controlled study of buspirone in generalized social phobia. Archives of general psychiatry, 59(12), 1136–1144. https://doi.org/10.1001/archpsyc.59.12.1136
Kushner, M. G., & Kim, S. W. (2001). Buspirone treatment of panic disorder: a meta-analysis. The American journal of psychiatry, 158(1), 53–59. https://doi.org/10.1176/appi.ajp.158.1.53
Rosenbaum, J. F., Biederman, J., Bolduc, E. A., Faraone, S. V., & Hirshfeld, D. R. (1998). A double-blind, placebo-controlled study of imipramine and buspirone in adults with attention-deficit hyperactivity disorder. Archives of general psychiatry, 55(3), 222–229. https://doi.org/10.1001/archpsyc.55.3.222